Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address the global problem of anti-microbial resistance (AMR), notes the launch of a series of videos and explainer documents from the UK BioIndustry Association (BIA) celebrating UK bioscience and revealing the cutting-edge R&D taking place in biotech companies around the UK.
Destiny Pharma has been chosen, alongside selected other UK biotech companies, to exemplify the UK’s leading status in key areas of biotechnology including antimicrobial resistance, genomics, cell and gene therapy and engineering biology. These videos and explainers cover strategic technologies being developed to offer potentially life-changing solutions to individuals and societies across the globe. The materials are available on the strategic technologies section of the BIA website.
Dr William Love, Chief Scientific Officer and Founder of Destiny Pharma, commented:
“We welcome the BIA’s continued support for companies investing in the development of much needed novel anti-infective treatments. The UK is one of the global leaders in antimicrobial resistance research and these materials give a true sense of the ground-breaking work being done here. Destiny Pharma is well-positioned to address in part this global issue through the continued clinical development of our novel XF drug platform.”
The full text of the BIA announcement is reproduced below:
BIA launches videos and explainer documents celebrating UK bioscience and revealing the cutting-edge R&D taking place in biotech companies around the UK
The UK BioIndustry Association (BIA) has today launched a series of four explainer booklets and five videos that celebrate the fantastic work taking place in UK bioscience companies to create innovative new drugs and treatments for patients.
The videos and explainers cover key areas of biotechnology including genomics, cell and gene therapy, antimicrobial resistance and engineering biology, as well as a video with the BIA charity of the year Parkinson’s UK looking at how artificial intelligence can help boost R&D into Parkinson’s.
All of the materials will be made available at the UK Bioscience Forum on Thursday 18 October, which brings together stakeholders from across the UK bioscience ecosystem for a day of panel discussions, networking and presentations. The keynote speaker for the event is Sir Mark Walport who will be updating attendees on how UK Research and Innovation (UKRI) will support the life sciences sector in the future.
BIA CEO, Steve Bates, said: “UK bioscience companies are at the forefront of these innovative, converging disciplines and these materials give a snapshot of the cutting-edge R&D that BIA member companies are engaged in to bring new treatments to patients.”
“The science profiled in these explainers has the potential to change the lives of patients living with diseases across the globe. The vibrancy of the UK bioscience ecosystem continues to attract top talent and investment from around the world and demonstrates the ability of our sector to weather political storms.”
Case studies and expert opinion for the explainers and videos came from the BIA’s Advisory Committees and working groups. The BIA’s Advisory Committees are crucial mechanisms for highlighting the most relevant issues facing bioscience companies. Committee members include influential experts from across the sector.
